Book a demo

Chemical intelligence powered by cypris.ai

4,17 Beta-dihydroxy-4-androstene-3-one

(8R,9S,10R,13S,14S,17S)-4,17-dihydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one · also: 4-Hydroxytestosterone, 4-Hydroxy Testosterone, 4-hydroxy-testosterone, 4-ANDROSTEN-4, 17beta-DIOL-3-ONE, 4,17beta-dihydroxyandrost-4-en-3-one, 4-Androstene-7alpha-17beta-diol-3-one

FormulaC19H28O3
Mol. weight304.43
PubChem CID160615
InChIKeyBQOIJSIMMIDHMO-FBPKJDBXSA-N
SMILESC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C(C(=O)CC[C@]34C)O
250Patents
38Research papers
9Patents - last 3 years
0Papers - last 3 years

Who owns the IP

The organizations most actively patenting around this compound, ranked by referenced patent volume.

#AssigneePatents
1Arena Pharmaceuticals Inc24
2Fontem Ventures BV14
3Intelligent Fingerprinting Ltd10
4Pfizer Italia SRL10
5Beckman Coulter Inc9
6King's College London8
7Research Foundation of the State University of New York8
8Harvard University7
9Massachusetts Institute of Technology6
10Bayer Pharma AG3

Explore the full landscape

This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.

Visit Cypris

Where innovation is concentrated

Patent classifications ranked by volume reveal the technical domains with the most active filing.

#CodeAreaPatents
1A61KMedicinal preparations159
2A61PTherapeutic activity (drug indications)153
3C07J47
4G01NInvestigating / analysing materials40
5C07DHeterocyclic compounds30
6Y02AClimate change adaptation20
7A24F19
8A61MDevices for introducing media into the body19
9B82YNanotechnology15
10A24B13

AI mapped opportunity space

This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.

See Cypris in action

Most-cited patents

Patents ranked by forward citations reveal the foundational inventions the field continues to build on.

TitleYearAssigneeCited by
4-hydroxytestosterone and esters thereof1956GD Searle LLC31
USE OF 4-HYDROXYTESTOSTERONE AS ANGIOGENESIS INHIBITOR2022CURADIS GMBH0

Who's driving the science

The most-published authors working with this compound, alongside their primary affiliations.

#AuthorAffiliationPapers
1Carolyn M. KlingeUniversity of Louisville3
2Boudewijn BurgeringUniversity Medical Center Utrecht2
3Eric W.‐F. LamLudwig Cancer Research2
4J. C. MittlerVeterans Biomedical Research Institute2
5Kiyoyuki TorigoeThe Wistar Institute1
6Maria Kristina ParrUniversity of Cologne2
7Wilhelm SchänzerGerman Sport University Cologne2
8Ali Vaziri‐GoharNew Mexico State University1
9Almut SchulzeCancer Research UK1
10Andrew HopeReNeuron (United Kingdom)1

Research leaders

This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.

See Cypris in action

The literature that defines it

The most-cited papers anchoring the scientific record for this compound.

Frequently asked questions

Common questions about this compound's patent and research landscape, answered from the underlying data.

What is the molecular formula and weight of 4,17 Beta-dihydroxy-4-androstene-3-one?

4,17 Beta-dihydroxy-4-androstene-3-one has a molecular formula of C19H28O3 and a molecular weight of 304.43. Its InChI Key identifier is BQOIJSIMMIDHMO-FBPKJDBXSA-N.

Which organizations hold the most patents related to this compound?

Arena Pharmaceuticals Inc holds the most patents with 24, followed by Fontem Ventures BV with 14 patents. Other leading patent holders include Intelligent Fingerprinting Ltd and Pfizer Italia SRL, each with 10 patents, and Beckman Coulter Inc with 9 patents.

What patent classifications are most commonly associated with this compound?

The most common patent classification is A61K (pharmaceutical preparations), appearing in 159 patents. This is followed by A61P (specific therapeutic activity of chemical compounds or medicinal preparations) in 153 patents, and C07J (compounds with at least one carboxylic acid group, or its salt or ester) in 47 patents.

What recent patent describes a novel application of 4-hydroxytestosterone?

A patent titled "USE OF 4-HYDROXYTESTOSTERONE AS ANGIOGENESIS INHIBITOR" was granted in 2022 by Curadis GmbH, describing the use of this compound as an angiogenesis inhibitor.

How many patents and papers in the literature address this compound?

The aggregate dataset contains 250 total patents related to this compound, with 9 patents filed in the last 3 years. There are 38 papers in the scientific literature (both through journal matching and text matching), though no papers were published in the last 3 years within this dataset.

Turn any compound into a complete chemical intelligence landscape

Go beyond static compound data. Cypris resolves identities, patents, papers, and commercial signals into one AI-powered view - so your team can move from a single chemical question to a complete R&D, IP, and market landscape.

Schedule a free trial